NEC infant formula lawsuit MDL 3026: where the cow's milk formula litigation actually stands

The NEC infant formula litigation involves one of the most heartbreaking case theories in modern mass tort practice. MDL 3026 (In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation), centralized in the U.S. District Court for the Northern District of Illinois before Judge Rebecca R. Pallmeyer, consolidates approximately 797 federal cases as of May 2026 alleging that cow's milk-based premature infant formulas manufactured by Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) cause necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating intestinal disease that destroys parts of the bowel, often requiring surgical removal of damaged intestine, with high mortality rates and permanent disability for survivors.

Federal MDL bellwether trials produced setbacks for plaintiffs in 2025-2026. The first three bellwether cases against Abbott Laboratories were dismissed on summary judgment after Judge Pallmeyer found that plaintiffs hadn't adequately established the existence of feasible alternatives to cow's milk-based formulas at scale during the relevant time periods. The summary judgment ruling effectively required plaintiffs to demonstrate not just that cow's milk formulas caused NEC, but that human milk-based alternatives could have replaced them in the NICU setting where premature infants are fed. The ruling has been controversial, plaintiffs argue donor human milk was widely available, while defendants argue the scale wasn't sufficient for routine NICU use.

The state court track has been substantially more favorable to plaintiffs. Major plaintiff verdicts include the March 2024 $60 million Illinois state court verdict against Mead Johnson (Enfamil), the July 2024 $495 million Missouri state court verdict against Abbott (Similac), and the April 2026 $70 million Chicago jury verdict against Abbott (Similac Special Care 24) for four mothers whose premature babies developed NEC. The contrast between the federal MDL summary judgment dismissals and the state court plaintiff verdicts has affected litigation dynamics, plaintiffs' counsel have increasingly directed cases to state courts where the procedural framework has been more receptive.

The first federal bellwether trial against Mead Johnson is scheduled for July 6, 2026 in Inman v. Mead Johnson, involving the death of Alexis Inman's son Daniel days after birth from NEC allegedly caused by Enfamil. The trial will be followed by an Abbott (Similac) bellwether on August 10, 2026. Two additional bellwethers are scheduled for August 3 and November 2, 2026, with another set for February 1, 2027. These bellwether outcomes will substantially affect whether the federal MDL framework remains viable for plaintiffs or whether state court filings will continue to dominate the litigation.

This is the science behind the NEC-formula connection, the procedural history of MDL 3026 and parallel state court litigation, the eligibility framework for filing claims, the strategic considerations for current and prospective plaintiffs, and what the upcoming bellwether trials mean for the litigation's future.

What is NEC and what is the case theory behind the infant formula lawsuit?

Necrotizing enterocolitis (NEC) is a gastrointestinal disease primarily affecting premature infants, causing intestinal tissue death with mortality rates of 20 to 40 percent. The case theory in MDL 3026 alleges that cow's milk-based premature infant formulas from Abbott (Similac) and Mead Johnson (Enfamil) significantly increase NEC risk compared to human milk-based feeding, and that both manufacturers failed to warn about this risk.

Necrotizing enterocolitis is a devastating gastrointestinal disease primarily affecting premature infants:

The disease. NEC causes inflammation and bacterial invasion of the intestinal wall, which can rapidly progress to tissue death (necrosis). The damaged intestinal tissue can perforate, allowing bacteria to enter the bloodstream and cause sepsis. NEC typically develops in the first weeks of life in premature infants, often after the introduction of enteral feeding.

Population affected. NEC primarily affects very premature infants, those born before 32 weeks gestation and especially those weighing less than 1,500 grams (very low birth weight) or less than 1,000 grams (extremely low birth weight). The disease affects approximately 5-10% of very low birth weight infants in the U.S.

Mortality and morbidity. NEC has a mortality rate of 20-40% depending on severity. Survivors often experience significant long-term complications including short bowel syndrome (after surgical removal of damaged intestine), developmental delays, cognitive impairment, and persistent gastrointestinal problems.

Treatment. Treatment involves intensive medical care including bowel rest, antibiotics, and in severe cases surgical removal of necrotic intestine. Surgery can result in permanent intestinal damage requiring long-term parenteral nutrition and other interventions.

Cow's milk-based formula causation. Plaintiffs allege that cow's milk-based premature infant formulas (Similac Special Care, Similac Special Care 24, Enfamil Premature, Enfamil Premature High Protein, similar specialized premature formulas) significantly increase the risk of NEC compared to human milk-based feeding.

Scientific basis. Multiple studies have shown that premature infants fed exclusively or predominantly with human milk (mother's milk or donor human milk) have substantially lower rates of NEC than infants fed cow's milk-based formula. Studies suggest NEC risk is reduced by 50-77% with human milk feeding.

Mechanism theory. The protective effect of human milk is attributed to multiple components: bioactive compounds that promote intestinal development, immunological factors that protect against infection, growth factors that support intestinal mucosal integrity, and the absence of cow's milk proteins that may trigger inflammatory responses in immature intestines.

Failure to warn theory. Plaintiffs allege that Abbott and Mead Johnson failed to warn:

• Parents about the increased NEC risk from cow's milk-based formulas
• Medical professionals about the disparity in NEC rates
• The general public about the safer alternatives available

Internal corporate knowledge. Discovery has produced internal documents from Abbott and Mead Johnson showing awareness of NEC studies and the protective effect of human milk for years before the litigation. Plaintiffs argue the companies should have updated labeling and informed consent practices based on this evidence.

What is the status of the federal MDL 3026 track?

MDL 3026, consolidated in April 2022 before Judge Pallmeyer in the Northern District of Illinois, includes approximately 797 pending cases as of May 2026. The first three Abbott bellwether cases were dismissed on summary judgment over the "feasible alternative" issue. The first Mead Johnson bellwether trial (Inman v. Mead Johnson) is scheduled for July 6, 2026, with additional bellwethers running through February 2027.

Illinois. Judge Rebecca R. Pallmeyer was assigned to oversee the litigation. The court has been managing the pre-trial work for the consolidated cases.

Case count. Approximately 797 cases pending as of May 2026, with roughly 950 total filings over time. The case count has remained relatively stable as some plaintiffs have moved cases to state court where the framework has been more favorable.

Bellwether selection. Judge Pallmeyer designated four bellwether cases:

• Two cases naming both Abbott and Mead Johnson
• One case naming only Mead Johnson (Enfamil)
• One case naming only Abbott (Similac)
• Three of the four are wrongful death cases (infant died from NEC); the fourth involves an infant who survived NEC but with severe complications.

Summary judgment dismissals. The first three federal bellwether cases against Abbott were dismissed on summary judgment. Judge Pallmeyer found that plaintiffs had failed to adequately demonstrate that feasible alternatives to cow's milk-based formulas existed at scale during the relevant time periods. The ruling was significant because it effectively created an additional element of proof for plaintiffs.

The "feasible alternative" issue. The summary judgment ruling has been controversial.

• Donor human milk was available through milk banks

• The federal government had supported milk bank expansion

• Some NICUs were successfully using donor human milk during the relevant periods

• The scale of donor human milk wasn't sufficient for routine NICU use

• Donor human milk has its own concerns (contamination, supply chain)

• The medical standard of care in the relevant period was cow's milk formulas

The court sided with defendants on the summary judgment ruling, but the framework's application to other cases (particularly cases involving more recent time periods when human milk was more available) remains uncertain.

Inman v. Mead Johnson, first remaining bellwether. Originally scheduled for February 2, 2026, the trial was rescheduled to July 6, 2026 following pretrial rulings. The case involves the death of Alexis Inman's son Daniel within days of birth from NEC allegedly caused by Enfamil. This will be the first MDL trial against Mead Johnson specifically.

Subsequent bellwether schedule. Abbott (Similac) bellwether August 10, 2026. Additional bellwethers August 3 and November 2, 2026, with another February 1, 2027.

Expert testimony. Judge Pallmeyer has issued various rulings on expert testimony admissibility. The court struck down one of defendants' proposed experts who challenged the causation link, citing inaccurate figures and unexplained criteria. The ruling supports plaintiffs' expert testimony framework for future bellwethers.

How have NEC infant formula cases performed in state court?

State court litigation has produced over $625 million in combined plaintiff verdicts as of mid-2026. Key wins include a $60 million Illinois verdict against Mead Johnson (March 2024), a $495 million Missouri verdict against Abbott (July 2024), and a $70 million Chicago verdict against Abbott (April 2026). The contrast with federal MDL summary judgment dismissals has driven increasing state court filings.

State court litigation has been substantially more favorable to plaintiffs:

Combined plaintiff verdicts. Over $625 million in NEC plaintiff verdicts across state courts as of mid-2026.

Why state courts favor plaintiffs. Several factors contribute to plaintiff success in state courts:

• State court pleading standards are sometimes more permissive
• State juries have shown sympathy for the human impact of NEC
• State court summary judgment standards differ from federal practice
• State courts haven't applied the "feasible alternative" requirement consistently

The state court success has drawn additional plaintiffs to state court filings, particularly in jurisdictions with favorable case law and jury pools.

What injuries are alleged in NEC infant formula lawsuits?

NEC litigation involves injuries ranging from infant death (with a 20 to 40 percent mortality rate) to severe surgical outcomes including short bowel syndrome, developmental delays, and chronic gastrointestinal complications. Cases involving infant death or extensive bowel resection surgery typically carry the highest case values, as reflected in state court verdicts exceeding $625 million combined.

NEC litigation involves a range of injury severities:

Wrongful death claims by parents on behalf of estates of deceased infants are common in the litigation.

Severe NEC requiring surgical intervention. Survivors who required bowel resection surgery to remove necrotic intestine.

Short bowel syndrome. Permanent consequence of bowel resection. The reduced intestinal length impairs nutrient absorption, often requiring long-term parenteral nutrition (IV feeding), dietary restrictions, and various complications.

Developmental delays. NEC and the associated medical treatments can produce neurodevelopmental complications. Severe NEC has been associated with cognitive impairment, motor delays, and similar developmental issues.

Chronic gastrointestinal complications. Survivors often have chronic gastrointestinal problems including strictures, dysmotility, and nutritional issues.

Other neonatal complications. Premature infants with NEC often experience multiple other complications including sepsis, respiratory problems, and various medical complications that compound the NEC injury.

Long-term medical care needs. Survivors typically require ongoing medical care for years or for life depending on injury severity.

The case values reflect the severity of these injuries. Cases involving infant death typically produce higher damages than cases involving milder NEC outcomes. The Missouri $495 million verdict and the Chicago $70 million verdict (for 4 plaintiffs) reflect the damages juries have been willing to award for these injuries.

Who is eligible to file an NEC infant formula lawsuit?

To file an NEC infant formula claim, the infant must have been born premature (typically before 37 weeks gestation), fed cow's milk-based formula such as Similac or Enfamil premature products in the NICU, and subsequently diagnosed with necrotizing enterocolitis. The strongest cases involve very premature infants (before 32 weeks) with severe NEC outcomes including death or surgical intervention.

The framework for filing NEC infant formula claims:

Premature birth. The infant was born premature, typically before 37 weeks gestation, often before 34 weeks for stronger cases. The strongest cases involve very premature infants (before 32 weeks).

Low birth weight. Infants weighing less than 2,500 grams at birth, often less than 1,500 grams (very low birth weight) for stronger cases.

Cow's milk-based formula feeding. The infant was fed Similac (Abbott products) or Enfamil (Mead Johnson products) premature formulas in the NICU. Documentation through NICU feeding records, hospital records, and pharmacy records.

Specific products implicated. The major implicated products include:

• Similac Special Care 24 (Abbott)
• Similac Special Care 30 (Abbott)
• Enfamil Premature High Protein (Mead Johnson)
• Enfamil Premature with iron (Mead Johnson)

NEC diagnosis. Documented diagnosis of NEC during NICU stay.

• Radiologic evidence (pneumatosis intestinalis, portal venous gas, or perforation)
• Surgical findings if surgical intervention occurred
• Pathology if intestinal tissue was examined

Temporal connection. NEC developed after exposure to cow's milk-based formula. The strongest cases involve clear temporal sequence with formula introduction followed by NEC development.

Injury severity. Significant injury including death, surgical intervention, short bowel syndrome, or other major complications. Mild NEC cases without significant long-term consequences are weaker.

Statute of limitations compliance. State-specific limitations periods apply. Many states have specific tolling provisions for injuries to minors, allowing claims to be filed years after the injury occurred. Wrongful death cases have their own limitations frameworks.

No significant alternative causation. Cases involving strong alternative explanations for NEC (severe infections, congenital intestinal abnormalities, etc.) face more difficult causation analysis.

A very premature infant (born before 32 weeks gestation) fed Similac Special Care or Enfamil Premature in the NICU, who developed severe NEC requiring surgical intervention, who either died from the disease or survived with long-term complications, with comprehensive NICU and follow-up medical records documenting the entire timeline.

What are the settlement projections for NEC infant formula cases?

No global settlement has been reached in the NEC infant formula litigation as of mid-2026. Total exposure for Abbott and Mead Johnson is estimated at $2 to $5 billion.

Per-case ranges. Highly variable based on case specifics:

• Cases involving infant death: $1 million to $5 million+ for typical cases, much higher for severe cases
• Cases involving severe NEC with surgical intervention and lasting complications: $500,000 to $3 million+
• Less severe cases: $100,000 to $500,000

The $495 million Missouri verdict and the $70 million Chicago verdict (for 4 plaintiffs) suggest per-case settlement potential.

Federal MDL uncertainty. The summary judgment dismissals in federal bellwether cases create uncertainty about federal MDL case values. The upcoming Inman bellwether (July 6, 2026) will provide additional information about federal MDL framework.

Total exposure. With ~800 federal MDL cases plus hundreds of state court cases, total exposure for Abbott and Mead Johnson is potentially in the $2-5 billion range depending on settlement framework. Both companies are major corporations with financial capacity for settlement.

How does the NEC litigation compare to other mass torts?

The NEC infant formula litigation is distinctive because its plaintiffs are voiceless premature infants who could not choose their feeding. It shares key structural features with other major mass torts, including internal corporate knowledge of risk (like Roundup), divergence between federal and state court outcomes (like talcum powder), and child-injury case theories (like Tylenol autism, though NEC has stronger causation science).

Most affected population is voiceless. The plaintiffs are infants who couldn't make decisions about their feeding. The cases proceed through parents and guardians on behalf of injured infants. This contrasts with most mass torts where adult plaintiffs make their own choices about product use.

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. NEC represents one of the most procedurally complex mass torts with divergence between federal MDL and state court outcomes.

What are the strategic considerations for NEC infant formula plaintiffs?

For parents and families of NEC-affected infants, the most important strategic decisions involve choosing between federal MDL and state court filing (given the divergence in outcomes), retaining counsel experienced in NEC litigation specifically, and thoroughly documenting the NICU feeding timeline. The July 6, 2026 Inman v. Mead Johnson bellwether trial will significantly shape federal MDL strategy going forward.

For parents and families of NEC-affected infants:

Consider both federal MDL and state court options. Given the procedural divergence, the strategic choice between federal MDL filing and state court filing has impact on case outcomes. Experienced counsel can evaluate which framework fits the specific case better.

Engage NEC-experienced counsel. The litigation is procedurally complex and emotionally challenging. Counsel with established NEC case experience handles these cases substantially better than general personal injury attorneys.

• Birth records and gestational age
• Feeding records (specific formulas used and timing)
• Treatment records including any surgical interventions
• Post-NICU follow-up care
• Long-term medical records for survivors

Wrongful death framework for deceased infants. Estates of deceased infants pursue wrongful death claims. The framework varies by state and includes economic damages, conscious pain and suffering, and parental damages.

Coordinate with medical providers. The NICU physicians, nurses, and other providers who treated the infant are important witnesses. Their support for the case theory strengthens the case substantially.

Don't delay filing. Statutes of limitations for minor injuries are typically tolled, but the tolling has limits.

Be realistic about timeline. Federal MDL bellwethers proceeding through 2026-2027. State court cases vary by jurisdiction. Plan for 2-4 year resolution timelines for most cases.

Coordinate with insurance and Medicaid recovery. Medical bills paid by insurance or Medicaid may be subject to subrogation rights. The recovery framework requires careful coordination with healthcare payers.

Watch the July 6, 2026 Inman trial. This will be the first federal MDL bellwether against Mead Johnson and the first remaining bellwether after the Abbott summary judgment dismissals. The outcome will substantially affect federal MDL framework going forward.

Have any settlement offer evaluated by experienced counsel before accepting.

For families of premature infants who developed NEC after cow's milk-based formula feeding, MDL 3026 and parallel state court litigation provide paths to compensation that recognize the serious harm caused by these products. The procedural complexity is with divergent outcomes between federal and state courts, but the underlying case theory is supported by strong scientific evidence and state court plaintiff verdicts. The Inman bellwether trial was scheduled for July 2026, while continuing state court litigation continues providing meaningful recovery for many plaintiffs. The work for affected families is engagement with experienced counsel, comprehensive documentation of the NICU and follow-up medical timeline, strategic decision-making about federal vs. state court filing, and patient navigation of the extended litigation timeline. For cases that proceed to favorable outcomes, the framework can produce substantial compensation that addresses the lifelong consequences of NEC for surviving infants and the catastrophic loss for families of infants who died from the disease.

This post is informational and does not constitute legal advice. If your family has been affected by NEC, consult a qualified attorney to evaluate your specific situation.